What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

"Historically, IL-23 inhibitors have required IV infusions at the start of therapy, which can create barriers to starting treatment or be burdensome for some patients and clinicians," said David T.

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...